The relationship between plexin C1 overexpression and survival in hepatocellular carcinoma: a Turkish oncology group (TOG) study
dc.authorid | Levent Korkmaz / 0000-0001-6931-6896 | en_US |
dc.authorscopusid | Levent Korkmaz / 57188703248 | |
dc.authorwosid | Levent Korkmaz / AGF-5971-2022 | |
dc.contributor.author | Turhal, Serdar Nazım | |
dc.contributor.author | Doğan, Mutlu | |
dc.contributor.author | Esendağlı, Güldal | |
dc.contributor.author | Artaç, Mehmet | |
dc.contributor.author | Korkmaz, Levent | |
dc.contributor.author | Çoşkun, Hasan Şenol | |
dc.contributor.author | Göker, Erdem | |
dc.date.accessioned | 2021-03-05T10:10:56Z | |
dc.date.available | 2021-03-05T10:10:56Z | |
dc.date.issued | 2021 | en_US |
dc.department | İstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Bilgisayar Mühendisliği Bölümü | en_US |
dc.description.abstract | Purpose Plexin C1 is a transmembrane receptor and plexin C1 overexpression might have role in carcinogenesis. Hepatocellular carcinoma (HCC) has poor prognosis because of its aggressive behavior and limited treatment options, especially in advanced stage. We recently documented that Plexin C1 was overexpressed in HCC. We aimed to evaluate the prognostic signifcance of Plexin C1 overexpression in HCC in the present study. Methods Plexin C1 overexpression was evaluated immunohistochemically on parafn-embedded blocks of the HCC patients. Plexin C1 immunohistochemical staining was scored. Plexin C1 overexpression staining intensity and prevalence were used for plexin scale staining evaluation and plexin scores were estimated according this staining scale. Plexin C1 score and its association with survival and clinicopathological features was assessed. Results Sixty-seven HCC patients with adequate tissue for pathological evaluation were included. Median age was 63 years with male predominance (male to female ratio was 4.75 (n 57/12). Well-diferentiated HCC (53.7%) patients had higher plexin C1 overexpression (p<0.05). Median OS was 22.1 months. Patients with lower plexin C1 score (<12) had shorter OS (17.5 vs 30.1 months, p=0.036). Neutrophil count, GGT, and PNR (platelet/neutrophil ratio) had prognostic signifcance (p=0.047, p=0.018, and p=0.045). Conclusion Plexin C1 overexpression is inversely correlated with grade in HCC. The patients with lower rate of Plexin C1 overexpression have worse survival outcome. It might be a prognostic factor in HCC. | en_US |
dc.identifier.citation | NazimTurhal, S., Dogan, M., Esendagli, G., Artac, M., Korkmaz, L., Coskun, H. S., Goker, E., PerranYumuk, F., Bilgetekin, I., Kose, F., Uncu, D., Kavgaci, H., Akyol, G., Ozet, A., & Yagci, T. (2021). The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study. Journal of gastrointestinal cancer, 10.1007/s12029-021-00602-4. Advance online publication. https://doi.org/10.1007/s12029-021-00602-4 | en_US |
dc.identifier.doi | 10.1007/s12029-021-00602-4 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.pmid | 33656690 | en_US |
dc.identifier.scopus | 2-s2.0-85131347050 | en_US |
dc.identifier.scopusquality | N/A | en_US |
dc.identifier.uri | https://doi.org/10.1007/s12029-021-00602-4 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12713/1515 | |
dc.identifier.volume | 52 | en_US |
dc.identifier.wos | WOS:000625053000002 | en_US |
dc.identifier.wosquality | N/A | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.institutionauthor | Korkmaz, Levent | |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.relation.ispartof | Journal of Gastrointestinal Cancer | en_US |
dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Hepatocellular Carcinoma | en_US |
dc.subject | Hcc | en_US |
dc.subject | Plexin | en_US |
dc.title | The relationship between plexin C1 overexpression and survival in hepatocellular carcinoma: a Turkish oncology group (TOG) study | en_US |
dc.type | Article | en_US |